Biodel (BIOD) Announces Initiations of BIOD-531 Phase 2b
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/20/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Biodel Announces Phase 2b Clinical Trial Initiation of BIOD-531, the Company's Concentrated, Ultra-Rapid-Acting, Prandial/Basal Combination Insulin Candidate
May 21, 2015 7:01 AM EDTDANBURY, CT -- (Marketwired) -- 05/21/15 -- Biodel Inc. (NASDAQ: BIOD) today announced the initiation of a Phase 2b clinical trial of BIOD-531, the Company's concentrated, proprietary, recombinant human insulin (RHI) based ultra-rapid-acting prandial/basal combination insulin candidate.
The Phase 2b trial, Study 3-250, is a randomized, open-label, parallel group study in patients with insulin-treated type 2 diabetes. Approximately 130 patients are targeted for enrollment at 25 U.S. investigative centers. Patients will be randomized to receive either BIOD-531 or Humalog® Mix 75/25 dosed twice daily. Patients will be... More
